26 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
1 | 35523987 | Discovery of novel targets and mechanisms of MEK inhibitor Selumetinib for LGG treatment based on molecular docking and molecular dynamics simulation. | 2022 May 6 | 1 |
2 | 33416182 | Targeting the mitogen‑activated protein kinase kinase and protein kinase A pathways overcomes acquired resistance to Selumetinib in low‑grade glioma cells. | 2021 Feb | 1 |
3 | 34666331 | The Synergistic Inhibitory Effect of Combining MK-2206 and AZD 6244 in MARIMO Cells Harboring a Calreticulin Gene Mutation. | 2021 | 1 |
4 | 29928418 | Cetuximab improves AZD6244 antitumor activity in colorectal cancer HT29 cells in vitro and in nude mice by attenuating HER3/Akt pathway activation. | 2018 Jul | 2 |
5 | 30021885 | PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. | 2018 Jul 18 | 1 |
6 | 30343534 | Fibroblast growth factor receptor 3-mediated reactivation of ERK signaling promotes head and neck squamous cancer cell insensitivity to MEK inhibition. | 2018 Dec | 1 |
7 | 28982310 | The dipeptidyl peptidase-IV inhibitor gemigliptin alone or in combination with NVP-AUY922 has a cytotoxic activity in thyroid carcinoma cells. | 2017 Oct | 1 |
8 | 26601868 | Treatment of Uveal Melanoma. | 2016 | 1 |
9 | 27422710 | Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer. | 2016 Oct | 1 |
10 | 25342139 | BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer. | 2015 Feb | 5 |
11 | 25933683 | Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models. | 2015 Jul | 1 |
12 | 25959272 | EGFR and MEK Blockade in Triple Negative Breast Cancer Cells. | 2015 Dec | 2 |
13 | 26137449 | Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth. | 2015 | 1 |
14 | 26250606 | Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer. | 2015 Nov | 3 |
15 | 23443802 | Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death. | 2013 May | 1 |
16 | 23444215 | Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma. | 2013 Apr 15 | 1 |
17 | 23602735 | Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathways. | 2013 Oct | 1 |
18 | 22082529 | Down-regulation of mitogen-inducible gene 6, a negative regulator of EGFR, enhances resistance to MEK inhibition in KRAS mutant cancer cells. | 2012 Mar | 2 |
19 | 22090271 | The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells. | 2012 Feb | 1 |
20 | 21628402 | The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma. | 2011 Jul 28 | 1 |
21 | 21828154 | Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy. | 2011 Sep 14 | 2 |
22 | 20885957 | Apoptosis induction by MEK inhibition in human lung cancer cells is mediated by Bim. | 2010 Sep 27 | 2 |
23 | 20959481 | Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. | 2010 Nov 1 | 7 |
24 | 21124782 | Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. | 2010 Nov 29 | 3 |
25 | 19755509 | Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. | 2009 Sep | 1 |
26 | 19783898 | High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886). | 2009 Nov | 4 |